Revance Therapeutics Inc (RVNC)

[rock mountain]

The data on Cervical Dystonia will renew interest and willingness by clinicians to test Daxxi for other indications.

Botox Prescription Information for CD states: " ... most subjects ... returned to pre-treatment status by 3 months post treatment" . Daxxi improvent to 20 - 24 weeks is cjlinically very relevant and will lead to huge excitement especially when paired with a decrease of dysphagia from 19% (Botox) to 2,7 and 4,2% (Daxxi).

This bodes very well for a strong interest to start new trials for the far more interesting indications such as spacticity, migrane, bladder dysfunction